Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Tdeltas is a UK-based Oxford spinout founded to hold and commercialize intellectual property around exogenous ketone ester technology branded as deltaG. The company develops and studies ketone monoester products intended to improve human physical performance, cognitive function, metabolism, and health, spanning applications in sports, wellness, and disease-related settings. Its core commercial focus appears to be proprietary ketone ester formulations sold directly or through partners and subsidiaries, including consumer-facing deltaG products in the United States. Tdeltas also maintains an R&D profile around biological and physical science research and has been described as active in clinical research related to ketone bodies.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Tdeltas.